Hawkeye is a medical technology company focused on the development of population-scale testing for the early detection cancer and inflammatory conditions. Cancer is a growing problem among individuals not traditionally considered to be at risk, such as non-smokers and younger individuals who are typically excluded from screening guidelines. The company’s lead program is in lung cancer detection.

Founded in 2019 and privately held, Hawkeye is based in Los Angeles with operations in Ireland. The Hawkeye team includes technologists, medical doctors, and thoracic surgeons with a three-decade track record of success in oncology, over 15 years in liquid biopsy biotech development, and hands-on business and regulatory experience spanning the US, Europe, and Asia.